General News

Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights

Mar 13, 2014

by Sophiris

In: General News, News, Press Releases

SAN DIEGO & VANCOUVER, British Columbia –(BUSINESS WIRE)– Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged

Read more

Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights

Nov 12, 2013

by Sophiris

In: General News, News, Press Releases

SAN DIEGO &VANCOUVER, British Columbia–(BUSINESS WIRE)–Sophiris Bio Inc. (Sophiris, NASDAQ:SPHS, TSX: SHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate),

Read more

Sophiris Bio Applies for Voluntary Delisting from TSX

Nov 5, 2013

by Sophiris

In: General News, News, Press Releases

SAN DIEGO &VANCOUVER, British Columbia–(BUSINESS WIRE)–Sophiris Bio Inc. (NASDAQ:SPHS) (TSX: SHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today

Read more